autologous CD8+ cytotoxic T lymphocyte therapy (Jiangsu CTL Biological Technology)

N/A

Report date: 2025/01/26 19:35:50

Base Information

Drug Nameautologous CD8+ cytotoxic T lymphocyte therapy (Jiangsu CTL Biological Technology)
Drug Alias Nameautologous non-genetically engineered CD8+ cytotoxic T lymphocytes (Jiangsu CTL Biological Technology)autologous CD8+ CTLs (Jiangsu CTL Biological Technology)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocytes stimulantsImmunostimulants
TargetsUpdating
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesJiangsu Sidier Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJiangsu Sidier Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A